Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 5 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Introduction | 10 | 1 |
| Critical Care Market to 2019 Global Overview | 11 | 2 |
| Critical Care Market to 2019 Geographical Landscape | 13 | 6 |
| Introduction | 13 | 1 |
| The US Critical Care Market | 14 | 1 |
| Revenue | 14 | 2 |
| Top Five European Countries Critical Care Market | 16 | 1 |
| Revenue | 16 | 2 |
| Japan Critical Care Market | 18 | 1 |
| Revenue | 18 | 1 |
| Critical Care Market to 2019 Albumin Market | 19 | 13 |
| Introduction | 19 | 2 |
| Marketed Albumin Products | 21 | 1 |
| Buminate | 21 | 1 |
| Zenalb | 21 | 1 |
| Human Albumin Biotest | 21 | 1 |
| AlbuRx | 22 | 1 |
| Albuminar | 22 | 1 |
| Albutein | 22 | 1 |
| Albuked | 23 | 1 |
| Vialebex | 23 | 1 |
| Albunorm | 23 | 1 |
| AlbuRAAS | 23 | 1 |
| Revenue | 24 | 2 |
| Cost of Therapy | 26 | 1 |
| China | 27 | 1 |
| Introduction | 27 | 1 |
| Strict Regulatory Reforms Leading to Tighter Supply | 27 | 1 |
| Fragmented Market Dominated by Overseas Players | 27 | 1 |
| Price of Albumin Likely to Remain High | 27 | 1 |
| Conclusion | 28 | 1 |
| India | 28 | 1 |
| Australia | 28 | 1 |
| Introduction | 28 | 1 |
| Rising Albumin Demand | 29 | 1 |
| Australian Albumin Market | 29 | 1 |
| Market Drivers and Barriers | 30 | 1 |
| Market Drivers | 30 | 1 |
| Costs Likely to Continue to Rise | 30 | 1 |
| Expanded Indications for Plasma-Derived Products to Amplify Demand | 30 | 1 |
| Growing and Aging Population to Increase Demand for Blood and Blood Products while also Constraining Supply | 31 | 1 |
| Market Barriers | 31 | 1 |
| Lack of Clinical Data for Use of Human Albumin in Various Clinical Settings will Restrict Market Growth | 31 | 1 |
| Critical Care Market to 2019 Antithrombin Concentrate Market | 32 | 15 |
| Introduction | 32 | 1 |
| Marketed Antithrombin Concentrate Products | 33 | 1 |
| Atryn | 33 | 2 |
| Aclotine | 35 | 1 |
| Anbinex | 35 | 1 |
| Antithrombin III | 36 | 1 |
| AT III | 36 | 1 |
| Kybernin P | 36 | 1 |
| Neuart | 37 | 1 |
| Thrombate III | 37 | 1 |
| Thrombotrol-VF | 37 | 1 |
| Revenue | 38 | 2 |
| Geographical Segmentation | 40 | 2 |
| Cost of Treatment | 42 | 1 |
| Treatment Usage Pattern | 43 | 1 |
| Diseased Population | 44 | 1 |
| Diagnosed Population | 44 | 1 |
| Patients on Antithrombin Concentrate | 44 | 1 |
| Drivers and Restraints | 45 | 1 |
| Drivers | 45 | 1 |
| Better Safety and Efficacy of AT Concentrate to Increase Uptake during the Forecast Period | 45 | 1 |
| Launch of Atryn to Drive the AT Concentrate Market | 45 | 1 |
| Restraints | 46 | 1 |
| Lack of Robust Scientific Evidence for the Usefulness of AT Concentrate | 46 | 1 |
| High Cost of Therapy with AT Concentrate Compared to Fresh Frozen Plasma | 46 | 1 |
| Critical Care Market to 2019 Fibrinogen Concentrate Market | 47 | 14 |
| Introduction | 47 | 1 |
| Marketed Fibrinogen Concentrates | 48 | 1 |
| Haemocomplettan/Riastap | 48 | 1 |
| Product Description | 48 | 1 |
| Mechanism of Action | 48 | 1 |
| Marketing Information | 48 | 1 |
| Safety Information | 48 | 1 |
| Clottafact | 48 | 1 |
| Other Marketed Fibrinogen Concentrates | 49 | 1 |
| FibroRAAS | 49 | 1 |
| Revenue | 49 | 2 |
| Geographical Segmentation | 51 | 2 |
| Market Segmentation | 53 | 2 |
| Cost of Treatment | 55 | 1 |
| Treatment Usage Pattern | 56 | 1 |
| Diseased Population | 57 | 1 |
| Diagnosed Population | 58 | 1 |
| Patients on Fibrinogen Concentrate | 58 | 1 |
| Drivers and Barriers | 59 | 1 |
| Drivers | 59 | 1 |
| Increasing Preference for Fibrinogen Concentrates | 59 | 1 |
| Increasing Market Demand Driven by Improved Diagnostic Techniques and Expanding Patient Base | 60 | 1 |
| Barriers | 60 | 1 |
| Lacking Availability of Robust Clinical Evidence Impedes Fibrinogen Concentrates Market | 60 | 1 |
| Critical Care Market to 2019 Prothrombin Complex Concentrate Market | 61 | 13 |
| Introduction | 61 | 1 |
| Oral Anti-Coagulant Reversal | 61 | 1 |
| Other Indications | 62 | 1 |
| Marketed Products | 63 | 1 |
| Beriplex P/N | 63 | 1 |
| Confidex | 63 | 1 |
| Profilnine SD | 63 | 1 |
| Uman Complex DI | 64 | 1 |
| Kaskadil | 64 | 1 |
| Octaplex 500 | 64 | 1 |
| Cofact | 64 | 1 |
| Feiba VH | 64 | 1 |
| Bebulin VH | 65 | 1 |
| Revenue | 65 | 2 |
| Revenue Breakdown | 67 | 1 |
| Geographical Segmentation | 68 | 1 |
| Cost of Therapy | 69 | 2 |
| Treatment Usage Pattern | 71 | 1 |
| Drivers and Restraints | 72 | 1 |
| Drivers | 72 | 1 |
| Expanding Indications for PCCs and Preference over Other Alternatives | 72 | 1 |
| Increased Use of PCCs for Various Bleeding Complications | 73 | 1 |
| Barriers | 73 | 1 |
| Lack of Clinical Data Regarding the Use of PCC in Various Possible Indications | 73 | 1 |
| Critical Care Market to 2019 Factor XIII Concentrate Market | 74 | 13 |
| Introduction | 74 | 1 |
| Marketed Products | 75 | 1 |
| Fibrogammin / Corifact | 75 | 1 |
| Product Description | 75 | 1 |
| Mechanism of Action | 75 | 1 |
| Safety Details | 75 | 1 |
| Revenue | 76 | 2 |
| Geographical Segmentation | 78 | 3 |
| Cost of Treatment | 81 | 2 |
| Treatment Usage Pattern | 83 | 1 |
| Diseased Population | 83 | 1 |
| Diagnosed Population | 84 | 1 |
| Drivers and Restraints | 85 | 1 |
| Drivers | 85 | 1 |
| rFXIII Approval in the EU, Anticipated Launch in the US and Increasing Patient Volume for Corifact to Drive the Market in Future | 85 | 1 |
| Restraint | 86 | 1 |
| Lack of Robust Data for Off-Label Usage of FXIII Concentrate | 86 | 1 |
| Critical Care Market to 2019 Research and Development Product Pipeline | 87 | 3 |
| Introduction | 87 | 2 |
| rFXIII (NovoThirteen) | 89 | 1 |
| Product Description | 89 | 1 |
| Mechanism of Action | 89 | 1 |
| Safety Details | 89 | 1 |
| Critical Care Market to 2019 Competitive Landscape | 90 | 3 |
| CSL Limited | 90 | 1 |
| Baxter International Incorporated | 90 | 1 |
| Grifols, SA | 90 | 1 |
| Octapharma AG | 90 | 1 |
| Kedrion SpA | 91 | 1 |
| Biotest | 91 | 1 |
| Laboratoire Fran ais de Fractionnement et de Biotechnologies | 91 | 1 |
| Bio Products Laboratory Limited | 91 | 1 |
| Sanquin Blood Supply Foundation | 91 | 1 |
| China Biologic Products, Incorporated | 92 | 1 |
| Hualan Biological Engineering, Incorporated | 92 | 1 |
| Shanghai RAAS Blood Products Company, Limited | 92 | 1 |
| Critical Care Market to 2019 Strategic Consolidation | 93 | 2 |
| Grifols Acquisition of Talecris Biotherapeutics in June 2011 | 93 | 1 |
| LFB Biotechnologies Acquisition of GTC Biotherapeutics in December 2010 | 93 | 1 |
| ViroPharma Expands Licensing Agreement with Sanquin Blood Supply Foundation in January 2010 | 94 | 1 |
| Critical Care Market to 2019 Appendix | 95 | 8 |
| Market Definitions | 95 | 1 |
| Abbreviations | 95 | 1 |
| Bibliography | 96 | 2 |
| Research Methodology | 98 | 2 |
| Coverage | 98 | 1 |
| Secondary Research | 98 | 1 |
| Primary Research | 99 | 1 |
| Therapeutic Landscape | 99 | 3 |
| Market | 101 | 1 |
| Geographical Landscape | 102 | 1 |
| Pipeline Analysis | 102 | 1 |
| Competitive Landscape | 102 | 1 |
| Expert Panel Validation | 102 | 1 |
| Contact Us | 102 | 1 |
| Disclaimer | 102 | 1 |